A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer-Reference-Cited by-同舟云学术

A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer

Published:2013-10-12 Issue:6 Volume:72 Page:1291-1297
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nakai Yousuke,Isayama Hiroyuki,Sasaki Takashi,Takahara Naminatsu,Hamada Tsuyoshi,Uchino Rie,Mizuno Suguru,Miyabayashi Koji,Yamamoto Keisuke,Mohri Dai,Kogure Hirofumi,Yamamoto Natsuyo,Hirano Kenji,Ijichi Hideaki,Tateishi Keisuke,Tada Minoru,Koike Kazuhiko

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-013-2313-8.pdf

Reference22 articles.

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol: Off J Am Soc Clin Oncol 15(6):2403–2413

2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 364(19):1817–1825. doi: 10.1056/NEJMoa1011923

3. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN, Harris M, Reni M, Ramanathan RK, Tabernero J, Hidalgo M, Van Cutsem E, Goldstein D, Wei X, Iglesias JL, Renschler MF (2013) Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). ASCO Meeting Abstracts 31 (4_suppl):LBA148

4. Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K (2012) A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106(12):1934–1939. doi: 10.1038/bjc.2012.183

5. Nakai Y, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Omata M, Koike K (2010) Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol 40(8):774–780. doi: 10.1093/jjco/hyq059

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of IGFBP2 in various cancers: a systematic review and meta‐analysis;Cancer Medicine;2022-05-11

2. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing;Cancer Medicine;2022-04-17

3. The correlation between common postoperative complications and quality of life, serum tumor markers, and prognosis in patients with esophageal cancer;Translational Cancer Research;2022-01

4. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2021-04

5. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study;Cancer Chemotherapy and Pharmacology;2020-07-06